Cognito Therapeutics Raises $196M in Series C Funding to Revolutionize Alzheimer’s Treatment with Non-Invasive Neuromodulation

Cognito Therapeutics, Inc. is proud to announce a major milestone in its journey to revolutionize the treatment of neurodegenerative diseases and improve human cognitive performance. The company has successfully raised $196,000,000 in its latest funding round—a testament to the growing confidence in its pioneering approach to non-invasive neuromodulation. As a trailblazer in this innovative field, Cognito Therapeutics is leveraging cutting-edge technology and breakthrough research to develop potentially transformative therapies for conditions such as Alzheimer’s disease. The funds will be strategically deployed to accelerate the company’s ambitious clinical programs, supporting the initiation of pivotal studies slated to begin in 2022. These studies aim to further validate the safety and efficacy of Cognito’s investigational therapeutic, which has already demonstrated promising potential in slowing or even halting cognitive decline and brain volume loss in preliminary clinical trials. Central to Cognito’s technological edge is its foundation in groundbreaking optogenetics research led by renowned MIT Professors Li-Huei Tsai and Ed Boyden. This scientific heritage, combined with the company’s recent FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease, underlines the transformative impact Cognito Therapeutics is poised to make in the neurodegenerative space. By infusing critical capital into research, development, and regulatory efforts, this funding round marks an exciting leap forward in the quest to tackle Alzheimer’s disease and related disorders, ultimately paving the way for a future where cognitive health can be preserved and enhanced through innovative, non-invasive interventions.